# US 5,707,983 A · Treatment of alzheimer's disease and modulation of immune system with .DELTA.5-androstenes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 5,707,983 A
- Document ID: US5707983A
- Status: Granted
- Kind: A
- Application number: 08/806,541
- Filed: 1997-02-24
- Granted: 1998-01-13
- Earliest claimed: 1990-08-29
- Assignees: Humanetics Corporation
- Inventors: Henry A. Lardy
- Web page: https://patentgrep.com/patent/US5707983A

## CPC

- A61K 31/5685: having an oxo group in position 17, e.g. androsterone
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Alzheimer's disease and immune deficiency disorders may be effectively treated by administering a .DELTA.5-Androstene-3.beta.-ol-17-one having a C.sub.7 substituent selected from the group consisting of oxo, hydroxy and groups convertible thereto by hydrolysis by administering a therapeutic amount of a .DELTA.5-Androstene-3.beta.-ol-17-one having a C.sub.7 substituent selected from the group consisting of oxo, hydroxy and groups convertible thereto by hydrolysis.

## Claims

### Claim 1

A method for treating a mammal with Alzheimer's disease comprising the step of administering to the mammal an effective amount of a steroid selected from the group consisting of .DELTA.5-Androstene-3.beta.-ol-17-one having a C.sub.7 substituent selected from the group consisting of oxo, hydroxy and groups convertible thereto by hydrolysis.

### Claim 2 (depends on 1)

The treatment method of claim 1 wherein the step of administering the steroid to a mammal comprises the step of administering the steroid to a human.

### Claim 3 (depends on 1)

The treatment method of claim 1 wherein the step of administering the steroid comprises the step of injecting the steroid.

### Claim 4 (depends on 1)

The treatment method of claim 1 wherein the step of administering the steroid comprises the step of inducing ingestion of the steroid.

### Claim 5

A method for retarding degeneration of the central nervous system of a mammal with Alzheimer's disease comprising the step of administering to the mammal an effective amount of a steroid selected from the group consisting of .DELTA.5-Androstene-3.beta.-ol-17-one having a C.sub.7 substituent selected from the group consisting of oxo, hydroxy and groups convertible thereto by hydrolysis.

### Claim 6 (depends on 5)

The treatment method of claim 5 wherein the step of administering the steroid to a mammal comprises the step of administering the steroid to a human.

### Claim 7 (depends on 5)

The treatment method of claim 5 wherein the step of administering the steroid comprises the step of injecting the steroid.

### Claim 8 (depends on 5)

The treatment method of claim 5 wherein the step of administering the steroid comprises the step of inducing ingestion of the steroid.

### Claim 9

A method for retarding loss of metal facilities of a mammal with Alzheimer's disease comprising the step of administering to the mammal a therapeutic amount of a steroid selected from the group consisting of .DELTA.5-Androstene-3.beta.-ol-17-one having a C.sub.7 substituent selected from the group consisting of oxo, hydroxy and groups convertible thereto by hydrolysis.

### Claim 10 (depends on 9)

The treatment method of claim 9 wherein the step of administering the steroid to a mammal comprises the step of administering the steroid to a human.

### Claim 11 (depends on 9)

The treatment method of claim 9 wherein the step of administering the steroid comprises the step of injecting the steroid.

### Claim 12 (depends on 9)

The treatment method of claim 9 wherein the step of administering the steroid comprises the step of inducing ingestion of the steroid.

### Claim 13

A method for retarding short term memory loss of a mammal with Alzheimer's disease comprising the step of administering to the mammal an effective amount of a steroid selected from the group consisting of .DELTA.5-Androstene-3.beta.-ol-17-one having a C.sub.7 substituent selected from the group consisting of oxo, hydroxy and groups convertible thereto by hydrolysis.

### Claim 14 (depends on 13)

The treatment method of claim 13 wherein the step of administering the steroid to a mammal comprises the step of administering the steroid to a human.

### Claim 15 (depends on 13)

The treatment method of claim 13 wherein the step of administering the steroid comprises the step of injecting the steroid.

### Claim 16 (depends on 13)

The treatment method of claim 13 wherein the step of administering the steroid comprises the step of inducing ingestion of the steroid.

### Claim 17

A method for retarding the advancement of disorientation in a mammal with Alzheimer's disease comprising the step of administering to the mammal a therapeutic amount of a steroid selected from the group consisting of .DELTA.5-Androstene-3.beta.-ol-17-one having a C.sub.7 substituent selected from the group consisting of oxo, hydroxy and groups convertible thereto by hydrolysis.

### Claim 18 (depends on 17)

The treatment method of claim 17 wherein the step of administering the steroid to a mammal comprises the step of administering the steroid to a human.

### Claim 19 (depends on 17)

The treatment method of claim 17 wherein the step of administering the steroid comprises the step of injecting the steroid.

### Claim 20 (depends on 17)

The treatment method of claim 17 wherein the step of administering the steroid comprises the step of inducing ingestion of the steroid.